Riskpilot← Back to searchSign inGet full accessCamyltec AB
ABActiveOrg 5592023930Drottningtorget 1Research and experimental development on natural sciences and engineering · NACE 7210Est. 20190 employees
Revenue 2025
SEK 40K
-33% vs 2024
EBITDA margin
25.3%
-63% vs 2024
Equity ratio
54.8%
Financial strength
Net profit 2025
SEK 8K
-66% vs 2024
| Revenue | SEK 40K | -33% |
| EBITDA | SEK 10K | -63% |
| Net profit | SEK 8K | -66% |
| Total assets | SEK 127K | +2% |
| Equity | SEK 70K | +13% |
| Employees | 0 | — |
Legal name
Camyltec AB
Org number
5592023930
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
12 april 2019
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-06-30
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna
Company purpose
Bolaget ska, direkt eller indirekt, bedriva utveckling, marknadsföring och försäljning av medicintekniska produkter samt annan därmed förenlig verksamhet.
Address
Drottningtorget 1
Email
bo.ekman@telia.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 35 | 40 | 35 | 60 | 40 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −4 | 5 | 8 | 27 | 10 |
| Depreciation & amort. | −0 | −0 | — | — | — |
| EBIT | −4 | 5 | 8 | 27 | 10 |
| Net financials | — | — | 0 | 0 | 0 |
| Profit before tax | −4 | 5 | 8 | 27 | 10 |
| Tax | −0 | −0 | — | −4 | −2 |
| Net profit | −4 | 5 | 8 | 24 | 8 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 53 | 52 | 51 | 125 | 127 |
| Equity | 25 | 30 | 38 | 62 | 70 |
| Long-term debt | 0 | 0 | — | — | — |
| Short-term debt | 28 | 22 | 13 | 63 | 57 |
| Total debt | 28 | 22 | 13 | 63 | 57 |
EBITDA margin
25.3%
This company
15.8%
Market median
+60% vs market
20212025
Equity ratio
54.8%
This company
38.2%
Market median
+43% vs market
20212025
Return on equity
11.6%
This company
18.4%
Market median
+37% vs market
20212025
Net profit margin
20.1%
This company
8.1%
Market median
+148% vs market
20212025
Asset turnover
0.31×
This company
1.12×
Market median
-72% vs market
20212025
Debt / equity
0.82×
This company
0.62×
Market median
+32% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-07-01 – 2025-06-30
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-07-01 – 2024-06-30
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-07-01 – 2023-06-30
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-07-01 – 2022-06-30
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-07-01 – 2021-06-30
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
PO Chief Executive Officer | Chief Executive Officer | 2026 |
| Former (1) | ||
SN Chief Executive Officer | Chief Executive Officer | 2022 – 2026 |
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
| Deputy Board Member | 2022 | |
| Board of Directors | 2026 | |
| Deputy Board Member | 2022 | |
| Chairman | 2026 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Camyltec AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Per Ola Camber | Chief Executive Officer | 0 companies |
| Sven Niklas Anders Axelsson | Chief Executive Officer | 0 companies |
| Birgitta Anna G Tennhammar Ekman | Deputy Board Member | 0 companies |
| Bo-Ragnar Tolf | Board of Directors | 0 companies |
| Birgitta Anna G Tennhammar Ekman | Deputy Board Member | 0 companies |
| Bo Magnus Ekman | Chairman | 0 companies |